Rapid Communication|Articles in Press

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators

Published:February 02, 2023DOI:


      • Among 171 patients with severe CFLD, 19 (11.1%) were not eligible for CFTR modulators.
      • All ineligible patients carried at least one mutation leading to complete loss of CFTR function.
      • There remains an unmet therapy need for ineligible patients with CFLD.


      Cystic-fibrosis-related liver disease (CFLD) is a variable phenotype of CF. The severe CFLD variant with cirrhosis or portal hypertension has a poor prognosis and life expectancy.
      CFTR modulator therapies are now available for people with CF and eligibility for such treatment is based on their CFTR genotype. We evaluated the genetic eligibility for elexacaftor, tezacaftor, ivacaftor (ETI), and ivacaftor (IVA) monotherapy in a previously reported CF cohort of 1591 people with CF of whom 171 with severe CFLD. Based on their CFTR mutations, 13% (N=184/1420) of subjects without CFLD and 11% (N=19/171) of those with severe CFLD are not eligible for either ETI or IVA therapy.
      The non-eligible patients without CFLD or with severe CFLD can currently not take advantage of the potential benefits of these new treatments. Although this study cannot provide any data regarding the effect of ETI or IVA on the progression of severe CFLD, the consequences for ineligibility of patients with extreme liver phenotype may be even more significant because of their poorer disease risk profile.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barry P.J.
        • Mall M.A.
        • Álvarez A.
        • Colombo C.
        • de Winter-de Groot K.M.
        • Fajac I.
        • et al.
        Triple therapy for cystic fibrosis phe508del gating and residual function genotypes.
        N Engl J Med. 2021; 385: 815-825
        • Heijerman H.G.M.
        • McKone E.F.
        • Downey D.G.
        • Van Braeckel E.
        • Rowe S.M.
        • Tullis E.
        • et al.
        Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
        Lancet. 2019; 394: 1940-1948
        • Middleton P.G.
        • Mall M.A.
        • Dřevínek P.
        • Lands L.C.
        • McKone E.F.
        • Polineni D.
        • et al.
        Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single phe508del allele.
        N Engl J Med. 2019; 381: 1809-1819
        • Mall M.A.
        • Mayer-Hamblett N.
        • Rowe SM.
        Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications.
        Am J Respir Crit Care Med. 2020; 201: 1193-1208
        • Regard L.
        • Martin C.
        • Burnet E.
        • J DaS
        • Burgel P.-.R.
        CFTR modulators in people with cystic fibrosis.
        Real-World Evid France Cells. 2022; 11: 1769
        • Graeber S.Y.
        • Renz D.M.
        • Stahl M.
        • Pallenberg S.T.
        • Sommerburg O.
        • Naehrlich L.
        • et al.
        Effects of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two f508del alleles.
        Am J Respir Crit Care Med. 2022;
        • Lindblad A.
        • Glaumann H.
        • Strandvik B.
        Natural history of liver disease in cystic fibrosis.
        Hepatology. 1999; 30: 1151-1158
        • Ye W.
        • Narkewicz M.R.
        • Leung D.H.
        • Karnsakul W.
        • Murray K.F.
        • Alonso E.M.
        • et al.
        Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis.
        J Pediatr Gastroenterol Nutr. 2018; 66: 122-127
        • Colombo C.
        • Alicandro G.
        • Oliver M.
        • Lewindon P.J.
        • Ramm G.A.
        • Ooi C.Y.
        • et al.
        Ursodeoxycholic acid and liver disease associated with cystic fibrosis.
        A Multicenter Cohort Study J Cyst Fibros. 2022; 21: 220-226
      1. Trikafta - Highlights of prescribing information. (accessed June 20, 2022).

      2. Clinical and Functional Translation of CFTR. June 20, 2022).

      3. Cystic Fibrosis Foundation. 2021 Cystic Fibrosis Foundation Patient Registry Highlights 2022. (accessed October 13, 2022).

        • Desai M.
        • Hine C.
        • Whitehouse J.L.
        • Brownlee K.
        • Charman S.C.
        • Nagakumar P.
        Who are the 10%? - non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
        Respir Med. 2022; 199106878
        • Khan H.H.
        • Mew N.A.
        • Kaufman S.S.
        • Yazigi N.A.
        • Fishbein T.M.
        • Khan K.M.
        Unusual cystic fibrosis transmembrane conductance regulator mutations and liver disease: a case series and review of the literature.
        Transplant Proc. 2019; 51: 790-793
        • West N.E.
        • Flume P.A.
        Unmet needs in cystic fibrosis: the next steps in improving outcomes.
        Expert Rev Respir Med. 2018; 12: 585-593